Brief: Nektar Therapeutics Announces Start Of Phase 3 Zenith Ad Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin In Moderate-To-Severe Atopic Dermatitis
21/07/2026 12:29
BRIEF-Nektar Therapeutics Announces Start Of Phase 3 Zenith Ad Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin In Moderate-To-Severe Atopic Dermatitis July 21 (Reuters) - Nektar Therapeutics NKTR.O:
NEKTAR THERAPEUTICS ANNOUNCES START OF PHASE 3 ZENITH AD PROGRAM EVALUATING NOVEL REGULATORY T-CELL BIOLOGIC REZPEGALDESLEUKIN IN MODERATE-TO-SEVERE ATOPIC DERMATITIS
NEKTAR THERAPEUTICS - INITIAL PHASE 3 TOPLINE DATA EXPECTED MID-2028; BLA SUBMISSION TARGETED FOR 2029
NEKTAR THERAPEUTICS - ZENITH AD PROGRAM TO ENROLL 1,530 PATIENTS ACROSS THREE PHASE 3 STUDIES
Source text: ID:nPn5CXZNQa
Further company coverage: NKTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says